Telomere-related genes play an important role in carcinogenesis and progression of prostate cancer (PCa). It is not fully understood whether genetic variations in telomere-related genes are associated with development and progression in PCa patients. METHODS: Six potentially functional single-nucleotide polymorphisms (SNPs) of three key telomere-related genes were evaluated in 1015 PCa cases and 1052 cancer-free controls, to test their associations with risk of PCa. Among 426 PCa patients who underwent radical prostatectomy (RP), the prognostic significance of the studied SNPs on biochemical recurrence (BCR) was also assessed using the Kaplan-Meier analysis and Cox proportional hazards regression model. The relative telomere lengths (RTLs) were measured in peripheral blood leukocytes using real-time PCR in the RP patients. RESULTS: TEP1 rs1760904 AG/AA genotypes were significantly associated with a decreased risk of PCa (odds ratio (OR): 0.77, 95% confidence interval (CI): 0.64-0.93, P = 0.005) compared with the GG genotype. By using median RTL as a cutoff level, RP patients with TEP1 rs1760904 AG/AA genotypes tended to have a longer RTL than those with the GG genotype (OR: 1.55, 95% CI: 1.04-2.30, P = 0.031). A significant interaction between TEP1 rs1713418 and age in modifying PCa risk was observed (P = 0.005). After adjustment for clinicopathologic risk factors, the presence of heterozygotes or rare homozygotes of TEP1 rs1760904 and TNKS2 rs1539042 were associated with BCR in the RP cohorts (hazard ratio: 0.53, 95% CI: 0.36-0.79, P = 0.002 and hazard ratio: 1.67, 95% CI: 1.07-2.48, P = 0.017, respectively). CONCLUSIONS: These data suggest that genetic variations in the TEP1 gene may be biomarkers for risk of PCa and BCR after RP.
INTRODUCTION
Although prostate cancer (PCa) is the second most commonly diagnosed cancer and the sixth most common cause of cancerrelated mortality among men worldwide, 1 only 10%-20% of diagnosed cases die from the disease, 2 whereas more patients live to develop recurrences. Patients with localized and locally advanced PCa are frequently treated with radical prostatectomy (RP). However, it is estimated that 430% of men undergoing RP will have disease relapse, also referred to as biochemical recurrence (BCR), defined as the first clinical indication of a rising serum level of PSA. 3 The risk of disease development greatly differs among individuals, and the heterogeneity in clinical behavior despite similar clinicopathologic characteristics further emphasizes the need to identify novel markers for recurrence. 4 Germline variation has been associated with risk of PCa and the recent use of genetic information to predict outcome and to guide treatment has also been steadily increasing in oncologic research and practice. 5 Telomeres are terminal, tandem nucleotide repeats (5′-TTAGGG-3′), in complex with telomere-binding proteins located at the ends of every chromosome, and are key components in the maintenance of chromosomal stability. 6, 7 In somatic cells, telomeres are shortening by 30-200 base pairs after each mitotic division due to the end-replication problem. 8 Progressive telomere shortening from cell division provides a barrier for tumor progression. Mounting evidence indicates that by initiating chromosomal instability, short and dysfunctional telomeres may be involved in prostate carcinogenesis. 9 In addition to be involved in PCa development, telomeres may also have a role in disease progression and tumor telomere alteration may prove to be a useful prognostic marker of post-prostatectomy BCR. [10] [11] [12] Theoretically, functional genetic variants that affect telomere elongation, activation of telomerase and configuration of telomeric proteins could lead to some accelerated functional changes responsible for cancer development and further growth advantages. Cancer genome-wide association studies have shown that single-nucleotide polymorphisms (SNPs) in the telomererelated genes are associated with risk of various cancers. [13] [14] [15] In addition, previous studies have identified several PCa susceptibility loci located in the telomerase reverse transcriptase (TERT) gene, the catalytic subunit of the telomerase ribonucleoprotein complex. 16, 17 However, the impact of functional genetic variants associated with PCa risk and recurrence in other telomere-related genes remains unclear.
There are two telomere-length maintenance mechanisms, including telomerase-based and alternative lengthening of telomeres recombinational mechanisms. TEP1 is a key component of the telomerase ribonucleoprotein complex, responsible for telomerase activity.
18 TEP1 also interacts directly with Bloom syndrome protein and modulates its helicase activity, suggesting that TEP1 has an important function in the alternative lengthening of telomere pathways. 19 TNKS and TNKS2 enhance the access of telomerase to telomeres, thereby having a role in telomere maintenance. 20 Variants in TEP1 and TNKS have also been found to be regulators of telomere length. 21, 22 Thus, we designed a case-control study using a candidate-gene approach, to test the hypothesis that potentially functional polymorphisms in three key telomere-related genes (TEP1, TNKS and TNKS2), which have previously been related to telomere length are associated with PCa risk. The relationship between these SNPs and BCR were further tested among a subset of patients who received RP.
MATERIALS AND METHODS

Study design and population
The study subjects were mostly from previously published case-control study. 23 Briefly, 1115 eligible patients recruited into this study were newly diagnosed and histopathologically confirmed primary prostate adenocarcinoma from Fudan University Shanghai Cancer Center between January 2005 and January 2012, of whom 1015 (92%) agreed to participate in this study ( Figure 1 ). All cases had received no prior chemotherapy or radiotherapy on recruitment. The tumor stage was determined according to criteria established by the American Joint Committee on Cancer tumornode-metastasis classification system (American Joint Committee on Cancer Staging Manual, sixth edition, 2002). Histopathological grading of the biopsy and RP specimens was performed according to the Gleason score system. The clinical information including Gleason score, serum PSA level at diagnosis, lymph node involvement and disease stage were abstracted from the archival medical records. In addition, 1143 age (± 5 years)-and geographical region-matched cancer-free ethnic Han Chinese controls were recruited from the Taizhou longitudinal study conducted during a similar time period. 24 Taizhou longitudinal study was a large prospective cohort initiated to explore the environmental and genetic risk factors for common non-communicable diseases. The sample size of the cohort will be at least 100 000 adults aged 30-80 years, drawn from the general residents of the districts of Taizhou. Baseline investigations included interviewer-administered questionnaire, anthropometric measurements and collection of buccal mucosal cells and blood specimens. Individuals with a known test of serum PSA 44 ng ml −1 present with or without abnormal digital rectal examination were excluded from the control group and those without response to the study participation were excluded (n = 91). All of the participants were interviewed with a questionnaire after a written informed consent was obtained. Blood samples were collected and processed as a routine practice by the Fudan University Shanghai Cancer Center Tissue Bank (for cases) and the Taizhou longitudinal study (for controls).
Patients were treated with radiation, androgen deprivation therapy and RP. A subset of clinically localized PCa patients who underwent RP (n = 441) between 2006 and 2009 were followed up by PSA at least every 3 months and disease-management information available from medical records; subjects were excluded if their medical records were not available (n = 15). The median follow-up time of the entire patient cohort was 37.7 months. BCR was defined as two consecutive PSA measurements 40.2 ng ml − 1 at an interval of 43 months and the date of this event was set to the first of these two test occasions. 25 This study was approved by the Institutional Review Board of Fudan University Shanghai Cancer Center.
SNP selection and genotyping
We searched the National Center for Biotechnology Information dbSNP database (http://www.ncbi.nlm.nih.gov/) for potentially functional SNPs and SNPinfo (http://snpinfo.niehs.nih.gov/), to identify the candidate SNPs based on the following three criteria: (1) located at the regulatory or coding region of genes (that is, the 5′-near gene, 5′-untranslated regions (UTRs), exons, splice sites, 3′-UTR and 3′-near gene); (2) the minor allele frequency ⩾ 5% in Chinese Han, Beijing descendants reported in HapMap; (3) affecting the activities of microRNA-binding sites in the 3′-UTR and transcription factor binding sites in the putative promoter region or changing the amino acid in the exons.
For the TEP1 gene, we chose rs1713418 and rs1760904; the former is located in the 3′-UTR region and the latter is located in the exon region. For the TNKS gene, we chose rs17734024 and rs1055328, both located in the 3′-UTR region. For the TNKS2 gene, we chose rs1539042 and rs3758499; the former is located in the 3′-UTR region and the latter is located in the exon region. All these six selected SNPs were genotyped by the TaqMan real-time PCR method as described previously. 26 Briefly, DNA isolation was performed by using the Qiagen Blood DNA Mini KIT (Qiagen, Valencia, CA, USA) with the buffy-coat fraction of the blood samples donated by the participants. The results with 499% call rates and 100% concordance for duplicated specimens were acceptable for further genotyping data analysis.
Measurement of relative telomere length
Relative telomere length (RTL) measurements were available in 426 patients who received RP. RTL as represented by the telomere repeat copy number to single-copy gene (that is, 36B4) copy number (T/S) ratio was measured using real-time quantitative PCR method described by Cawthon 27 on an Applied Biosystems 7900HT. The PCR reaction mixture consisted of SYBR Green Mastermix (Applied Biosystems, Grand Island, NY, USA), 100 nmol l
Tel-1, 900 nmol l − 1 Tel-2, 400 nmol l − 1 36B4d, 400 nmol l − 1 36B4u and 7 ng of genomic DNA. The thermal cycling profile was 95°C for 10 min followed by 40 cycles of 95°C for 15 s and at 56°C (for telomere) or 58°C (for 36B4) for 1 min. Following amplification, a dissociation curve confirmed the specificity of the reaction. During each run, negative and positive controls, a calibrator DNA sample and a standard curve were included. For each standard curve, twofold serial dilutions of a reference DNA sample were used to produce a standard curve in each reaction. Two main steps were involved in RTL quantification: first, the T/S ratio was determined for each sample based on the standard curve. Second, the ratio for each sample was normalized to the calibrator DNA to standardize sample values across all reaction plates. The laboratory personnel were blinded to BCR status. R 2 for each standard curve was ⩾ 0.99.
Statistical analysis
For all subjects, the χ 2 -test was used to assess differences in the frequency distributions of the selected demographic variables and genotypes of six SNPs between the cases and controls. The Hardy-Weinberg equilibrium for genotype distribution in controls was tested by a goodness-of-fit χ 2 -test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by univariable and multivariable unconditional logistic regression models, to evaluate associations between the genotypes and risk of PCa without and with adjustment for confounding factors (age, smoking status and body mass index), respectively. Further stratification analyses were conducted to calculate the associations of SNP genotypes with PCa risk by demographic and clinicopathologic variables, followed by the homogeneity Q-tests. Based on the observed genotypes, haplotype frequencies were generated using Statistical Analysis Software PROC HAPLOTYPE (SAS Institute, Cary, NC, USA) to calculate ORs for haplotypes associated with PCa risk. The interaction was also assessed by using a likelihood ratio test to compare models with and without the interaction terms. TEP1 polymorphisms and prostate cancer C Gu et al For the 426 patients who received RP, the association between each SNP and BCR of PCa was assessed with hazard ratios and 95% CI estimated by Cox proportional hazards regression analysis. The assumption of proportionality of the hazards was tested by using scaled Schoenfeld residuals. To evaluate the effects of genetic variations beyond the clinical factors to influence PSA recurrence, multivariate analyses were adjusted for stage, Gleason score, lymph node involvement and PSA at diagnosis. The probability of freedom from the recurrence was estimated using the Kaplan-Meier method and the significance was determined using the log-rank test. For estimating recurrence risk, the time-dependent variable was defined as time from the date of RP to the first reported evidence of recurrence and patients without the event were censored at their last follow-up update. Spearman's rank correlation was used to investigate associations between RTL and age. RTL was categorized into dichotomies, tertile and quartile, based on the distribution.
Finally, the Bonferroni correction and false-positive report probability were used to assess the false-positive findings. 28 All statistical analyses were performed with SAS software (version 9.1; SAS Institute).
RESULTS
The characteristics of all study participants are presented in Table 1 Table 1 ) and the TNKS haplotype GG was significantly associated with the PCa risk.
Stratification and interaction analysis
We detected a statistically significant interaction between age and TEP1 rs1713418 variant genotypes in the stratification analysis (Supplementary Table 2 ). Overall, the TEP1 rs1713418 AG/GG genotypes were associated with a 32% increased risk of PCa among younger individuals but was associated with 29% reduced risk of PCa among older ones, a finding of heterogeneity supported by additional homogeneity tests and confirmed by the interaction analyses (Supplementary Table 3 ). Such a statistical evidence of SNP-age interaction was not observed for other SNPs. To account for chance associations from multiple comparisons, the Bonferroni correction was performed and false-positive report probability values for significant findings at different prior probability levels were shown in Supplementary Table 4 .
Genetic variations and risk of PCa BCR Telomere erosion has been reported to be a prognostic predictor of early likelihood of post-RP BCR.
12-14 Here we evaluated the effects of genetic variants in telomere-related genes in a cohort of 426 clinical localized PCa patients who underwent RP. Among 100 (23.5%) men who experienced unfavorable outcomes, the median time to the BCR was 28.4 months (range, 2.1-55.7 months). PSA levels, pathologic stage, lymph node involvement and Gleason score were significantly associated with the BCR (P o0.01) (Supplementary Table 5 ). We performed multivariable analyses for each SNP and found significant associations of TEP1 rs1760904 and TNKS2 rs1539042 genotypes with risk of PCa BCR (Table 3) . The TEP1 rs1760904 displayed the most significant association, with a 0.53-fold decreased risk (95% CI: 0.36-0.79) of PCa progression associated with the AG/AA genotypes, compared with the GG genotype. Kaplan-Meier curves and log-rank tests were used to show the probability of BCR stratified by TEP1 rs1760904 genotypes (P = 0.005, Figure 2) . No statistically significant associations were found for the other SNPs analyzed.
Genetic variations and RTL To investigate whether the RTL had prognostic significance, PCa patients who underwent RP were categorized into dichotomies, tertiles and quartiles based on their RTL distribution (range, 0.06-2.06). RTL was inversely associated with age (r = − 0.40, P o0.001). When participants were dichotomized according to the median RTL value, significant differences in RTL by genotype of TEP1 rs1760904 were observed (Table 4) . Longer RTL showed a significantly higher proportion of the AG/AA genotypes, compared with that of the GG genotype (OR: 1.55, 95% CI: 1.04-2.30). The association between RTL and risk of BCR did not differ significantly Table 5 ).
DISCUSSION
In the present study, we identified that the TEP1 rs1760904 variant genotypes were significantly associated with PCa risk. Individuals with one or two copies of the TEP1 rs1760904 A allele were at 0.77-fold lower PCa risk than the GG homozygotes. Genetic variants of TEP1 have been previously examined in relation to bladder, hepatocellular and breast cancer risk. 18, 22, 29 This SNP is non-synonymous and causes a substitution of proline to serine (Ser1195Pro), which is likely to affect TEP1 structure and influence telomerase, as well as BLM helicase activity. Telomere shortening can initiate tumor growth and constrain PCa progression. Therefore, it is a likely candidate for the source of the complex genetic changes underlying the phenotypic diversity of PCa. 9 Moreover, we found that the TEP1 rs1760904 might be an independent predictive factor for post RP BCR in the study population. In the Kaplan-Meier and multivariable Cox hazards regression analyses, this SNP predicted BCR risk in patients with localized PCa treated by RP after adjustment for the known clinical predictors of recurrence. Although TEP1 has not been functionally implicated in PCa to date, we speculated that telomere length was a physiological modulator involved in the association between genetic variations in the TEP1 gene and PCa recurrence. Subsequent real-time quantitative PCR assays consistently showed TEP1 rs1760904 was associated with RTL in 426 RP patients. Although this association became borderline after Bonferroni correction was applied, the current study showed evidence of men with the AG/AA genotypes tended to have longer telomeres than the men with the GG genotype. This finding may contribute to a more accurate prediction of clinical outcome and enhance the selection of the high-risk patients who may benefit from more aggressive adjuvant therapy and more intensive follow-up.
In addition to age, smoking and obesity also accelerate telomere shortening by increasing systemic oxidative burden. 30, 31 Thus, we conducted exploratory analyses of SNP-environment interactions with smoking, body mass index and age. It is noteworthy that there was a significant interaction between TEP1 rs1713418 and age. Mounting evidence suggests that cancer is an aging-associated disease, and that cancer and aging share many molecular pathways. 32 Physiologically, telomeres undergo shortening with each cell division and consequently telomeres shorten with age. An age-related decline in telomere length may promote genetic instability and affect the risk of malignancies.
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TEP1 codes for protein that has a key role in telomerase that is responsible for catalyzing the addition of new telomeres to chromosomes. 18 These results support the presence of biological interactions between telomere attrition and age on PCa development and recurrence (Figure 3) . Accounting for risk factors and TEP1 polymorphisms and prostate cancer C Gu et al their potential interactions with genetic factors could result in improved discrimination in risk stratification. TNKS2 regulates telomere homeostasis by binding to TRF1, the negative regulator of telomere length. 20 Discovery of roles for TNKS2 in cellular processes involved in proliferation and survival has raised the possibility of using TNKS2 inhibitors as novel anticancer therapeutics. 34 In multivariable analyses, heterozygotes or rare homozygotes of the TNKS2 rs1539042 variant allele were at 1.55-fold increased risk for BCR. An SNP located specifically in the 3′-UTR of the TNKS2 gene, such as rs1539042, may change the affinity of a miRNA-binding site so as to repress translation or destabilize mRNA. In fact, miR-20a had been shown to modulate the translation of TNKS2 mRNA via the binding sites in the 3′-UTR and promote colony formation, cellular invasion and migration of cancer cells. 35 Four previous studies have examined the association between genetic variants in the TNKS2 genes and cancer risk, and the results have not been entirely consistent. 18, [36] [37] [38] However, only one study has investigated the effect of TNKS2 polymorphisms on cancer prognosis. In this study, TNKS2 rs2066276 located in the promoter of the TNKS2 gene, in partial linkage disequilibrium with rs1539042 (r 2 = 0.41 and D' = 1), showed a significant correlation with histologic grade of but not susceptibility to breast cancer. 36 These data support the hypothesis that clinical outcomes may benefit from TNKS2 inhibition in the treatment of PCa.
Germline genetic variation has the potential to be a marker for predisposition to aggressive disease and may provide insights into biological pathways of initiation and progression of PCa. 39 Given the potential genetic heterogeneity existing in tumor tissues, the use of inherited variation to predict treatment response is appealing, which could potentially allow for more tailored PCa therapies. Several SNPs have yet been identified, which adds clinically significant increment to the prognostic power of currently used clinical indicators and seem to improve the predictive accuracy of preoperative nomograms for tumor progression. 39, 40 As initial studies investigating prognostic endpoints were inconsistent, 39, 41, 42 we chose the clinical endpoint of BCR when designing the study. Although BCR itself portends a variable prognosis and does not always predict systemic recurrence, 3 its use as a primary outcome after RP is significant, because BCR is the primary trigger for further intervention with salvage radiation therapy or androgen-deprivation therapy. 43 Moreover, in light of the relatively high proportion of men experiencing BCR, 3 a prognostic biomarker that accurately reflects the risk of BCR would have a direct clinical impact by determining which patients are at highest risk of BCR for further treatment. With this information, an informed conversation can be held between patients and physicians on whether or not to initiate the needed therapy immediately due to an increased risk or whether or not an observation period is preferable. Indeed, these findings that variations in TEP1 rs1713449 and TNKS2 rs1539042 may help to accurately define the patient population that would benefit from adjuvant therapy in men receiving RP is intriguing and worthy of further studies. In agreement with previous studies, 2,3,40 we found that PSA, Gleason score, lymph node involvement and disease stage were among the most important predictors of BCR. Thus, the results of this study are strengthened by these well-known prognostic factors of PCa recurrence. However, there were some limitations to consider in interpreting these results. One potential drawback of the current study was that we did not investigate all genes involved in the telomere pathway and some possible significant SNPs of other telomere-related genes might be missed. Additional studies of the role of other telomere-related gene variants in PCa are warranted. In addition, several studies have indicated a relationship between smoking and telomere shortening, 30, 44, 45 whereas we found no interaction between smoking and telomere length in the present study. This finding may be explained by the limited sample size and further studies would be needed to definitively evaluate these relationships in larger sample sizes. Furthermore, this study did not have sufficient statistical power to identify the associations between telomererelated gene SNPs and outcome after prostate radiotherapy; a larger study focus on the radiation therapy would be necessary to answer this question. Finally, our study was based on the leukocytes telomere length only and not on the prostate tissue telomere length. As there is an intra-individual synchrony in telomere length across the somatic tissues of humans as evidenced by the strong correlations between the telomere lengths in all tissue types. 46 Moreover, the rates of telomere shortening are similar in the somatic tissues. 46 However, future work aims to directly describe the relationships between prostate tissue, leukocytes telomere lengths and PCa BCR cases.
CONCLUSIONS
In conclusion, we identified that TEP1 rs1760904 was associated with both risk of PCa and RTL. In addition, SNPs of TEP1 and TNKS2 also influenced risk of tumor progression independent of the known clinicopathologic predictors. This work was built on the importance of telomere-related genetic variants in the PCa biology and it is essential that our findings are replicated in independent studies with longer follow-up periods for cancer outcomes. Relevant functional studies will clarify the link between telomere-related genes and PCa risk and recurrence. If confirmed, these findings will further advance the understanding of PCa occurrence and prognosis, with the ultimate goal of better individualizing treatment for PCa.
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